Media Kit

Download Backgrounder

TheraPsil 1


Here are some of the topics TheraPsil, is ready to discuss.

  • How British Columbia/Canada is at the forefront of legal/decriminalized psychedelic therapies
  • Drug Discovery and the efficacy of psychedelic intervention for palliative care patients.
  • Psychedelic Medicine in Mental Health creating access for Canadian patients
  • Canadian Psychedelics Recent Section 56(1) exemption
  • Learnings from being First Movers in the Psychedelic Space, lawyers, advocates, and patient rights
  • Safeguarding the medical use of Psilocybin, ensuring that Investments are sound and preventing the over commodification of “psychedelic medicine”
  • COVID-19 and the After Effects of Isolation on mental health in Canada
  • The right to die in Canada
  • Potential for Psychedelic medical discovery and research on Canadian economy

Topics that TheraPsil would be able to provide comment/insights about…

  • The Pre-Clinical Trial
  • Process (where we are at in terms of determining medical efficacy for psychedelic interventions)
  • Patient rights in Canada and end-of-life Cancer Care
  • Palliative Medicine
  • Organic versus Synthetic Molecules
  • Drug Discovery Timeline
  • Legal Challenge Timeline

Mission: TheraPsil’s 4 Pillars.

COMPASSIONATE ACCESS: Establish safe, compassionate, and legal access to psychedelic-assisted therapy for those in medical need.

PUBLIC EDUCATION: Increase awareness of general public and health care professionals about the merits and limitations of psychedelic-assisted therapy.

PROFESSIONAL TRAINING: Developing safe, simple, and effective protocols for credentialed health professionals across Canada to deliver psilocybin-assisted therapy, in collaboration with other active organizations.

RESEARCH: Facilitate research and evaluation, in collaboration with Canadian and international partners.

Vision: Why They Exist.

  • Canadians in palliative care with severe psychological distress deserve access to effective new therapies, in consultation with a physician, which can improve their quality of life/death.
  • When effective therapy involves a prohibited/controlled substance, we challenge the laws that are in conflict with science and compassionate care.
  • Care providers must work collaboratively with patients toward healing vs merely the suppression of psychological trauma, addiction, illness, and pain.

TheraPsil’s Values.





  • Freedom of citizens to exercise their right to try therapies and make their own choices about their personal health and wellbeing
  • Courage to fight for that right
  • Compassion for patients in medical need and with a palliative diagnosis
  • Responsibility to mitigate suffering and promote the well-being of patients


Lobby Health Minister Patty Hajdu to accept section 56(1) exemptions for the right to access psilocybin on compassionate medical grounds, on behalf of TheraPsil patients who have requested access to end-of-life psychedelic paliation.

The Result? Success, received approval for first four patients as of August 4th 2020.

Pursue legal avenue for patients seeking the medicinal use of psilocybin and psychedelic therapies.

Potentially challenge the Charter to allow for the medical cultivation, distribution, and administering of psilocybin medicine

Blog Posts.

How could establishing “connection” via psychedelic medicine help 4 Canadian cancer patients?

Press Releases.

TheraPsil launches program to assist patients in accessing legal, psilocybin-assisted psychotherapy, 06/01/20

Recent News.

4 Palliative Canadians approved for end of life psilocybin therapy through section 56(1) ; First legal medical exemptions for psilocybin in Canada since 1970’s (August 4, 2020)

Today marks Day 100: Dying patients still waiting on acknowledgement from Federal Health Minister, Patty Hajdu in response to applications for access “psilocybin-assisted-therapy” (July 30, 2020)

Establishing connections via psychedelic medicine for palliative care patients (July 30, 2020)

Palliative Patients await August 4 Canadian Government decision on psilocybin access (July 30, 2020)

PRESS RELEASE: Palliative Canadians await August 4th decision on psilocybin mushroom approval – TheraPsil urges Health Minister to ‘do the right thing’ (July 29, 2020)

Can Magic Mushrooms be used to treat mental illness (July 21, 2020)

Letter from Marcus Powlowski to Minister Patty Hajdu (July 21, 2020)

Anxiety On The Rise As Cancer Patients Wait (July 18, 2020)

Psychedelic Therapists Petition Government For Permission To Dose Themselves In Order To Better Treat Patients (July 15, 2020)

Prospective Media Opportunities.

Here are some of the topics TheraPsil, is ready to discuss.

  • Drug Discovery and Intellectual Property development in research.
  • Psychedelic Medicine in Mental Health
  • Canadian Psychedelics and the hunt for novel compounds.
  • Learnings from being First Movers in the Psychedelic Space
  • Psilocybin Investment Opportunities in Canadian “Mush Rush”
  • Covid-19 and the After Effects of Isolation on mental health in Canada
  • Drug-resistant PTSD, Depression and Addiction
  • Economy in Canada

The Team.

Board of Directors

Bruce Tobin – Founder & Chair
Emma Hapke, MD
Sean O’Sullivan, MD
Pauline Goh, MA


Spencer Hawkswell – Executive Director
Holly Bennett – Communications Director
Andras Lenart – Research & Evaluation Liaison
Adam Farquharson – Web Developer
Peg Peters – Media Strategist
Tara Portelli – Community Education Coordinator

Clinical Advisors

James Kerr, MA
Dr. Hayden Rubensohn, MD
Krista Stogryn, MD
Richard Miners, Ph.D.
Mark Cornfield, MD, FRCPC
Susan McBride, RN, MTS RSW
Donna Rosenthal, BA
Neil Hanon, MD FRCPC

Legal Team

Paul Lewin – General Counsel
Jack Lloyd
Dan Stein
Robert W.E Laurie
David Wood
Henria Stephens
Emily Amirkhani

Follow on Social Media.





Subscribe To Our Newsletter

Schedule Your Free Discovery Call, Or Website Accessibility Audit.